Compare Abeona Therapeutics Inc (ABEO) vs American Superconductor Corporation (AMSC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs American Superconductor Corporation — how do they compare? Abeona Therapeutics Inc trades at $6.73 (market cap $373.32M), while American Superconductor Corporation trades at $35.3 (market cap $1.72B). The key difference: American Superconductor Corporation is far larger — about 4.6× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, American Superconductor Corporation nearer its low. Which is the better fit depends on your goals.
| ABEO | AMSC | |
|---|---|---|
Market Cap | $373.32M | $1.72B |
Sector | Health | Technology |
52-Week High | $7.23 | $66.68 |
52-Week Low | $4.17 | $25.95 |
Enterprise Value | $228.22M | $1.59B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
AMSC trades at $38.13, up 2.75% today, but technical indicators signal bearish momentum with selling pressure across moving averages. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.30 surpassing expectations of $0.19. Revenue grew 34% year-over-year to $299.2 million in fiscal 2025, while net income margin expanded significantly to 44.73%. However, negative cash flow of -$6.90 million in 2025 and high EV/EBITDA of 71.09 raise valuation concerns.
The outlook remains mixed with analyst consensus leaning bullish (53% buy ratings) but technical weakness suggesting near-term pressure. Key opportunities include strong backlog growth (up 40% to $280 million) and expanding AI/energy infrastructure demand. Risks include acquisition-driven revenue growth, high valuation multiples, and insider selling activity. Earnings growth remains the primary catalyst for sustained upside momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About American Superconductor Corporation
AMSC provides energy technology solutions for smarter and cleaner power grids. It offers wind turbine electronic controls and advanced grid systems that enhance the reliability and efficiency of renewable energy networks.
Read more on AMSC →
